The presentation is part of the filing. The data presented, although cloaked in lots of other stuff, is that they have a drug with statistically relevant clinical data that addresses an unmet medical need (stage 1, compensated Cirrhosis) that has a patient population of 1.5-2M people in the United States alone.
The p value for the population without varices is 0.01, which is very strong and sends a clear message that the drug works on this population.
It's also really fortunate that they ran the 2 mg/kg dose in the trial along with the 8 mg/kg dose because, had they only run the 8 mg/kg dose they would have failed miserably.
With these results and the line of credit there is essentially no risk in this stock as the company is worth far more than the current market cap. In spite of my continued reservations about Traber I bought shares this week to hold for the long term.
News 
Market Data 
Discover 
